CCTG trials in development update 2025 Q2

2025 Q2 Planned trials

• ALC9 myeloMATCH (HEMATOLOGIC) Q3 2025 | Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
• CE10 VIGOR (BRAIN) Q4 2025 | VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
• CO33 BATTMAN (GASTRO-INTESTINAL) Q4 2025 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
• HN14 REVERT (HEAD & NECK) Q2 2026 | Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
• MD1 myeloMATCH (HEMATOLOGIC) Q2 2026 | CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
• ME18 (MELANOMA) Q3 2026 | Selective Index Node Resection vs Lymph Node Dissection after Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma. The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3)
• PAC5 (GASTRO-INTESTINAL) 2026 | Lanreotide for the Prevention of Postoperative Pancreatic Fistula
• SC30 RATIONAL-PT (SUPPORTIVE CARE) Q3 2025 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial
• SC31 (SUPPORTIVE CARE) Q3 2025 | Using SMART to optimize the stepped care delivery of TEMPO – a Tailored, dyadic, wEb-based physical activity and self-Management PrOgram for men with prostate cancer and their caregivers (TEMPO)
• SR8 HARMONY (SARCOMA) Q1 2027 | Hypofractionated Alternative Radiation with MOdulation of Neoadjuvant/perioperative immunotherapY in Sarcoma (HARMONY)
• MA42 (BREAST) Q4 2025 | No Chemotherapy in Intermediate-risk HR + HER2- Early Breast Cancer Treated with Ribociclib (NoLEEta)
• IND246 (SELECTED SOLID TUMORS) Q4 2025 | GCAR1, a chimeric antigen receptor (CAR) t-cell therapy in selected relapsed/refractory GPNMB-expressing alveolar soft-part sarcoma, renal cell carcinoma, and triple negative breast cancer
• IND245 (MANTLE CELL LYMPHOMA) Q4 2025 | Sonrotoclax and Zanubrutinib in patients with relapsed/refractory mantle cell lymphoma receiving standard of care CAR-t cell therapy

Recently activated trials

• BR38 Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer More >>
• HE2 STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC) More >>
• PR26 Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) More >>
• SKC1 Neoadjuvant Immunotherapy with Response-Adapted Treatment vs Standard-Of-Care Treatment For Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma More >>